Scholarlink

<p>Interleukin-37 (IL-37) exists in various human tissues and organs and exhibits extensive anti-inflammatory activity. Recombinant IL-37 ameliorates the insulin resistance and inflammation associated with obesity and type 2 diabetes (T2DM). However, the specific role and underlying mechanisms of different doses of IL-37 in macrophage inflammatory response in T2DM remain to be discovered. In our study, we determined the dual role of IL-37 in macrophage inflammatory response both in vitro and vivo. We discovered that very low doses of IL-37 (10 ng/ml in vitro and 100 ng/ml in vivo) are sufficient to elicit significant anti-inflammatory effects. Conversely, high-dose IL-37 promotes the inflammatory response in macrophages. Specifically, a high dose of IL-37 (1000 ng/ml) did not improve blood glucose levels, intraperitoneal glucose tolerance, or insulin tolerance, nor did it reduce the number of islet macrophages in the T2DM model. Mechanistically, our in vitro and in vivo experiments demonstrated that high-dose IL-37 inhibited the activation of key signaling molecules such as phosphatase and tensin homolog (PTEN), AMP-activated protein kinase(AMPK), and signal transducer and activator of transcription 3 (STAT3) via preferential binding to IL-18Rα in macrophages. In contrast, low-dose IL-37 resulted in the activation of these signaling pathways. Collectively, these findings highlight low-dose IL-37 as a potential therapeutic agent to ameliorate inflammatory reactions and metabolic disturbances during T2DM. However, it is crucial to note that high-dose IL-37 may have no beneficial effects or could even exacerbate the condition.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

High-dose IL-37 promotes inflammatory activity of macrophage via Preferential ligation of the IL-18Rα

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月1日

查看全文
  • Yu Zhang,
  • Beixi Shi,
  • Yaxin Bi,
  • Xiaxin Wu,
  • Xiangning Li,
  • Jinfeng Wu,
  • Jiahui Qiu,
  • Zhijie Lin,
  • Guotao Lu,
  • Weijuan Gong

摘要

Interleukin-37 (IL-37) exists in various human tissues and organs and exhibits extensive anti-inflammatory activity. Recombinant IL-37 ameliorates the insulin resistance and inflammation associated with obesity and type 2 diabetes (T2DM). However, the specific role and underlying mechanisms of different doses of IL-37 in macrophage inflammatory response in T2DM remain to be discovered. In our study, we determined the dual role of IL-37 in macrophage inflammatory response both in vitro and vivo. We discovered that very low doses of IL-37 (10 ng/ml in vitro and 100 ng/ml in vivo) are sufficient to elicit significant anti-inflammatory effects. Conversely, high-dose IL-37 promotes the inflammatory response in macrophages. Specifically, a high dose of IL-37 (1000 ng/ml) did not improve blood glucose levels, intraperitoneal glucose tolerance, or insulin tolerance, nor did it reduce the number of islet macrophages in the T2DM model. Mechanistically, our in vitro and in vivo experiments demonstrated that high-dose IL-37 inhibited the activation of key signaling molecules such as phosphatase and tensin homolog (PTEN), AMP-activated protein kinase(AMPK), and signal transducer and activator of transcription 3 (STAT3) via preferential binding to IL-18Rα in macrophages. In contrast, low-dose IL-37 resulted in the activation of these signaling pathways. Collectively, these findings highlight low-dose IL-37 as a potential therapeutic agent to ameliorate inflammatory reactions and metabolic disturbances during T2DM. However, it is crucial to note that high-dose IL-37 may have no beneficial effects or could even exacerbate the condition.